Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States

Autor:	David Ashkin, Pennelyn Onderko, Charles A. Peloquin, Marie-Claire Rowlinson, Patricia Macias, Connie A. Haley, Betsy A. Jones, Roshni Jaimon, Maria E. Gomez, Supriya Jasuja, Neela D. Goswami, Elaine Darnall
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	Microbiology (medical) medicine.medical_specialty Tuberculosis Epidemiology 030231 tropical medicine Antitubercular Agents lcsh:Medicine linezolid lcsh:Infectious and parasitic diseases Food and drug administration South Africa 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Antibiotic resistance BPaL Internal medicine Tuberculosis Multidrug-Resistant Research Letter Humans Medicine lcsh:RC109-216 030212 general & internal medicine antimicrobial resistance Diarylquinolines bedaquiline bacteria drug monitoring business.industry Drug resistant tuberculosis lcsh:R Novel 6-Month Treatment for Drug-Resistant Tuberculosis United States medicine.disease United States tuberculosis and other mycobacteria Regimen Infectious Diseases chemistry Pretomanid Linezolid Nix-TB pretomanid Bedaquiline business
Zdroj:	Emerging Infectious Diseases, Vol 27, Iss 1, Pp 332-334 (2021) Emerging Infectious Diseases
ISSN:	1080-6059 1080-6040
Popis:	The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f79f2f02e141e749e62d983c07a84261 https://wwwnc.cdc.gov/eid/article/27/1/20-3766_article Zobrazit plný text záznamu Plný text ve formátu PDF